3utu Citations

Beyond heparinization: design of highly potent thrombin inhibitors suitable for surface coupling.

ChemMedChem 7 1965-73 (2012)
Cited: 9 times
EuropePMC logo PMID: 22907907

Abstract

During extracorporeal circulation, when blood comes in contact with artificial surfaces, patients receive a standard treatment with anticoagulants to avoid blood coagulation. Dialysis patients in particular are systemically treated with heparin up to four times a week, causing a high burden for the body. For potential anticoagulant modification of external materials, such as dialysis equipment, a series of highly potent thrombin inhibitors was developed. All inhibitors share the general formula arylsulfonyl-P3-Pro-4-amidinobenzylamide, where P3 is glycyl or a trifunctional amino acid residue in L-configuration. Among this series, several derivatives inhibit thrombin with Ki values of less than 1 nM. Specificity measurements revealed that this inhibitor type is highly specific for thrombin with negligible activity against related trypsin-like serine proteases. X-ray analysis of the most potent analogue in complex with thrombin demonstrated that the N-terminal arylsulfonyl group occupies the aryl binding site, whereas the P3 side chain is directed into the solvent and therefore is well suited for further coupling. Based on their in vitro profile, these inhibitors are suitable candidates for the development of hemocompatible materials with anticoagulant properties.

Articles - 3utu mentioned but not cited (5)

  1. PSnpBind: a database of mutated binding site protein-ligand complexes constructed using a multithreaded virtual screening workflow. Ammar A, Cavill R, Evelo C, Willighagen E. J Cheminform 14 8 (2022)
  2. Diversity-guided Lamarckian random drift particle swarm optimization for flexible ligand docking. Li C, Sun J, Palade V. BMC Bioinformatics 21 286 (2020)
  3. Divide-and-conquer strategy for large-scale Eulerian solvent excluded surface. Zhao R, Wang M, Tong Y, Wei GW. Commun Inf Syst 18 299-329 (2018)
  4. PSnpBind-ML: predicting the effect of binding site mutations on protein-ligand binding affinity. Ammar A, Cavill R, Evelo C, Willighagen E. J Cheminform 15 31 (2023)
  5. Assessing How Residual Errors of Scoring Functions Correlate to Ligand Structural Features. Shulga DA, Shaimardanov AR, Ivanov NN, Palyulin VA. Int J Mol Sci 23 15018 (2022)


Articles citing this publication (4)

  1. Thrombin-Inhibiting Anticoagulant Liposomes: Development and Characterization. Endreas W, Brüßler J, Vornicescu D, Keusgen M, Bakowsky U, Steinmetzer T. ChemMedChem 11 340-349 (2016)
  2. Congress 30th Annual GP2A Medicinal Chemistry Conference. O'Boyle NM, Helesbeux JJ, Meegan MJ, Sasse A, O'Shaughnessy E, Qaisar A, Clancy A, McCarthy F, Marchand P. Pharmaceuticals (Basel) 16 432 (2023)
  3. Exploiting activity cliffs for building pharmacophore models and comparison with other pharmacophore generation methods: sphingosine kinase 1 as case study. Mousa LA, Hatmal MM, Taha M. J Comput Aided Mol Des 36 39-62 (2022)
  4. Visualization of Topological Pharmacophore Space with Graph Edit Distance. Nakano H, Miyao T. ACS Omega 7 14057-14068 (2022)